Market Cap (In USD)
1.06 Billion
Revenue (In USD)
30 Thousand
Net Income (In USD)
-54.36 Million
Avg. Volume
1.14 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.02-18.51
- PE
- -
- EPS
- -
- Beta Value
- 0.998
- ISIN
- US82835W1080
- CUSIP
- -
- CIK
- 1671858
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
- Employee Count
- -
- Website
- https://ars-pharma.com
- Ipo Date
- 2020-12-04
- Details
- ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
More Stocks
-
MAP
-
AFFYAffymax, Inc.
AFFY
-
ROVRRover Metals Corp.
ROVR
-
RMGGFResolute Mining Limited
RMGGF
-
WGMCFWinston Gold Corp.
WGMCF
-
CUII
-
WHN
-
MODIRUBBERModi Rubber Limited
MODIRUBBER